Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Elijah Sanches, Besir Topal, Monika Proczko, Pieter S. Stepaniak, Rich Severin, Shane A. Phillips, Ahmad Sabbahi, Juan Pujol Rafols & Sjaak Pouwels. (2020) Endothelial function in obesity and effects of bariatric and metabolic surgery. Expert Review of Cardiovascular Therapy 18:6, pages 343-353.
Read now
Read now
Slobodan M. Janković, Danka Tešić, Jelena Anđelković & Marina Kostić. (2018) Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review. Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 461-474.
Read now
Read now
Richard B. Lipton, Alan Brennan, Stephen Palmer, Anthony J. Hatswell, Joshua K. Porter, Sandhya Sapra, Guillermo Villa, Neel Shah, Stewart Tepper & David Dodick. (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics 21:7, pages 666-675.
Read now
Read now
Gregory S. Pokrywka. (2018) PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. Postgraduate Medicine 130:3, pages 287-298.
Read now
Read now
Dasha Cherepanov, Tanya G.K. Bentley, Wendy Hsiao, Pin Xiang, Frank O’Neill, Yi Qian, Nicole Yurgin & David Beenhouwer. (2018) Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review. Current Medical Research and Opinion 34:3, pages 459-473.
Read now
Read now
Dong-Churl Suh, Scott K. Griggs, Emmett R. Henderson, Seung-Mi Lee & Taehwan Park. (2018) Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert Review of Pharmacoeconomics & Outcomes Research 18:1, pages 51-69.
Read now
Read now
Jason Doctor & Joanna P. MacEwan. (2017) Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies. Current Medical Research and Opinion 33:9, pages 1635-1642.
Read now
Read now
Borislav Borissov, Michael Urbich, Boryana Georgieva, Svetoslav Tsenov & Guillermo Villa. (2017) Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*. Journal of Market Access & Health Policy 5:1.
Read now
Read now
Articles from other publishers (37)
Emilio Ortega, Bogdan Vlacho, Ray Puig Treserres, Manel Mata-Cases, Andreu Altes, Dídac Mauricio & Josep Franch-Nadal. (2023) Severe hypertriglyceridemia prevalence at a primary care setting in Catalonia, Spain. Journal of Clinical Lipidology 17:6, pages 777-787.
Crossref
Crossref
Xiao-ling Cai, Yi-fei Xiang, Xiao-fang Chen, Xue-qin Lin, Bi-ting Lin, Geng-yu Zhou, Lin Yu, Yan-song Guo & Kai-yang Lin. (2023) Prognostic value of triglyceride glucose index in population at high cardiovascular disease risk. Cardiovascular Diabetology 22:1.
Crossref
Crossref
T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov & N. Z. Musina. (2023) Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 16:1, pages 17-34.
Crossref
Crossref
Osung Kwon, Wonjun Na, Jaehee Hur, Ju Hyeon Kim, Tae Joon Jun, Hee Jun Kang, Hojoon Lee & Young-Hak Kim. (2021) Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data. Cardiovascular Drugs and Therapy 37:1, pages 129-140.
Crossref
Crossref
Sajid Iqbal, Hani Mohamed Sabbour, Mohsin Sohail Siddiqui, Alia Al Tikriti, Raul D. Santos & Adam Buckley. (2022) The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population. Clinical Therapeutics 44:10, pages 1297-1309.
Crossref
Crossref
Jean Grégoire, Salimah Champsi, Manon Jobin, Laura Martinez, Michael Urbich & Raina M. Rogoza. (2022) Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada. Advances in Therapy 39:7, pages 3262-3279.
Crossref
Crossref
Xiaoyu Xi, Xin Wang, Wenwen Xie, Yu Jia, Santiago Zuluaga Sanchez, Laura Martinez & Quanming Zhao. (2022) Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective. Cardiovascular Drugs and Therapy.
Crossref
Crossref
Iiro Toppila, Liisa Ukkola‐Vuoti, Julia Perttilä, Outi Törnwall, Juha Sinisalo, Juha Hartikainen & Seppo Lehto. (2022) Cardiovascular event rate and death in high‐risk secondary prevention patient cohort in Finland: A registry study. Clinical Cardiology 45:4, pages 342-351.
Crossref
Crossref
Ahmed Alghamdi, Bander Balkhi, Abdulaziz Altowaijri, Nasser Al-shehri, Lewis Ralph, Emily-Ruth Marriott, Michael Urbich, Fawaz Aljanad & Rima Aziziyeh. (2021) Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. PharmacoEconomics - Open 6:2, pages 277-291.
Crossref
Crossref
Bhavani Shankara Bagepally & Akhil Sasidharan. (2021) Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. European Journal of Clinical Pharmacology 78:3, pages 351-363.
Crossref
Crossref
Ulf Landmesser, Peter Lindgren, Emil Hagström, Ben van Hout, Guillermo Villa, Peter Pemberton-Ross, Jorge Arellano, Maria Eriksson Svensson, Mahendra Sibartie & Gregg C Fonarow. (2022) Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal - Quality of Care and Clinical Outcomes 8:1, pages 31-38.
Crossref
Crossref
Reza Rezayatmand, Ghasem Yadegarfar, Masoumeh Ghasemirad & Farzaneh Mohammadi. (2022) The use and the cost of outpatient diagnostic procedures for cardiovascular diseases in Isfahan province: A utilization study. Journal of Education and Health Promotion 11:1, pages 245.
Crossref
Crossref
Therese Aubry-de Maraumont, Luis Miguel Camacho-Cordero, Mónica Alva-Esqueda, Adolfo Gabriel Hernández-Garduño, Jorge Antonio Guzmán-Caniupan & Fernando Carlos-Rivera. (2022) Evaluación económica de evolocumab en pacientes con enfermedad cardiovascular de alto riesgo con hipercolesterolemia primaria y dislipidemia mixta no controlados. Cardiovascular and Metabolic Science 33:2, pages 52-63.
Crossref
Crossref
Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Emanuela Arcangeli, Laura Martinez, Francesc Sorio Vilela & Francesco Saverio Mennini. (2021) Cost-utility analysis of evolocumab in patients with ASCVD in Italy. Global & Regional Health Technology Assessment 8, pages 155-167.
Crossref
Crossref
Xiaoding Xu, Yunxia Dong, Ningning Ma, Weiwen Kong, Chuwei Yu, Likun Gong, Jing Chen & Jin Ren. (2021) MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice. Metabolism 119, pages 154768.
Crossref
Crossref
Bradley SarakAnamaria Savu, Padma Kaul, Finlay A. McAlister, Robert C. Welsh, Andrew T. Yan & Shaun G. Goodman. (2021) Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes 14:4.
Crossref
Crossref
Clara Marquina, Ella Zomer, Sandra Vargas-Torres, Sophia Zoungas, Richard Ofori-Asenso, Danny Liew & Zanfina Ademi. (2020) Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. PharmacoEconomics 38:10, pages 1095-1113.
Crossref
Crossref
Peter P. Toth, Steven R. Jones, Maria Laura Monsalvo, Mary Elliott‐Davey, J. Antonio G. López & Maciej Banach. (2020) Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. Journal of the American Heart Association 9:5.
Crossref
Crossref
M. Campioni, I. Agirrezabal, R. Hajek, J. Minarik, L. Pour, I. Spicka, S. Gonzalez-McQuire, P. Jandova & V. Maisnar. (2019) Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. The European Journal of Health Economics 21:2, pages 219-233.
Crossref
Crossref
Eun Ji Kim & Anthony S. Wierzbicki. (2020) The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Therapeutic Advances in Chronic Disease 11, pages 204062232092456.
Crossref
Crossref
Alexander Dressel, Burkhard Schmidt, Nina Schmidt, Ulrich Laufs, Felix Fath, M. John Chapman, Tanja B. Grammer & Winfried März. (2019) Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort. Vascular Pharmacology 120, pages 106566.
Crossref
Crossref
Maria Lindh, Jonas Banefelt, Kathleen M Fox, Sara Hallberg, Ming-Hui Tai, Mats Eriksson, Guillermo Villa, Maria K Svensson & Yi Qian. (2019) Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. European Heart Journal - Quality of Care and Clinical Outcomes 5:3, pages 225-232.
Crossref
Crossref
Jennifer G. Robinson, Manju Bengularu Jayanna, Alan S. Brown, Karen Aspry, Carl Orringer, Edward A. Gill, Anne Goldberg, Laney K. Jones, Kevin Maki, Dave L. Dixon, Joseph J. Saseen & Daniel Soffer. (2019) Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. Journal of Clinical Lipidology 13:4, pages 525-537.
Crossref
Crossref
Ella Zomer, Danny Liew, Andrew Tonkin, James M. Trauer & Zanfina Ademi. (2019) The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. International Journal of Cardiology 285, pages 1-5.
Crossref
Crossref
Alanna M. Chamberlain, Sarah S. Cohen, Susan A. Weston, Kathleen M. Fox, Pin Xiang, Jill M. Killian & Yi Qian. (2019) Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease. The American Journal of Cardiology 123:11, pages 1739-1744.
Crossref
Crossref
David Sinning & Ulf Landmesser. (2019) Is There a Need to Revise Goals in the Management of Dyslipidemias?. Current Cardiology Reports 21:6.
Crossref
Crossref
Rachid Essalmani, Elodie Weider, Jadwiga Marcinkiewicz, Ann Chamberland, Delia Susan-Resiga, Anna Roubtsova, Nabil G. Seidah & Annik Prat. (2018) A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice. Biological Chemistry 399:12, pages 1363-1374.
Crossref
Crossref
Sung-Kwan Oh, A-Ra Cho, Yu-Jin Kwon, Hye-Sun Lee & Ji-Won Lee. (2018) Derivation and validation of a new visceral adiposity index for predicting visceral obesity and cardiometabolic risk in a Korean population. PLOS ONE 13:9, pages e0203787.
Crossref
Crossref
Radya Kumar, Andrew Tonkin, Danny Liew & Ella Zomer. (2018) The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. International Journal of Cardiology 267, pages 183-187.
Crossref
Crossref
Lieven Annemans, Chris J Packard, Andrew Briggs & Kausik K Ray. (2018) ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal 39:27, pages 2546-2550.
Crossref
Crossref
Anthony S. Wierzbicki, Timothy M. Reynolds & Adie Viljoen. (2018) An update on trials of novel lipid-lowering drugs. Current Opinion in Cardiology 33:4, pages 416-422.
Crossref
Crossref
Parth Shah. (2018) Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases. Current Cardiology Reports 20:7.
Crossref
Crossref
Seth J. Baum & Christopher P. Cannon. (2018) PCSK9 inhibitor valuation: A science‐based review of the two recent models. Clinical Cardiology 41:4, pages 544-550.
Crossref
Crossref
Anthony S. Wierzbicki. (2017) The challenges of proprotein convertase subtilisin–kexin-9 inhibitors for lipid guidelines and models of care. Current Opinion in Lipidology 28:6, pages 470-476.
Crossref
Crossref
Amitava Banerjee. (2017) Challenges for learning health systems in the NHS. Case study: electronic health records in cardiology. Future Hospital Journal 4:3, pages 193-197.
Crossref
Crossref
. (2017) Optimizing Specialty Drug Use. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37:8, pages 973-975.
Crossref
Crossref
Jason N. Doctor & Joanna P. MacEwan. (2017) Limitations of Traditional Health Technology Assessment Methods and Implications for the Evaluation of Innovative Therapies. SSRN Electronic Journal.
Crossref
Crossref